Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay Rowasa Supply Problems Get Help From Axcan Shipments To U.S.

Executive Summary

Canadian firm Axcan has begun supplying 5-aminosalicylic acid suppositories to U.S. patients who have been unable to obtain Solvay's 5-ASA rectal suppository Rowasa.

You may also be interested in...



Solvay To Submit Audits To FDA Shortly In Effort To Be Removed From AIP List

Solvay has indicated that the independent audits analyzing stability data generated by its manufacturing facilities will be submitted shortly to FDA as a step in being removed from the agency's application integrity policy list.

Solvay To Submit Audits To FDA Shortly In Effort To Be Removed From AIP List

Solvay has indicated that the independent audits analyzing stability data generated by its manufacturing facilities will be submitted shortly to FDA as a step in being removed from the agency's application integrity policy list.

Solvay $123 Mil. Unimed Buy Brings Three Drugs, 40 Reps

Solvay is paying $123 mil. in cash for Unimed's three marketed products, one pending NDA and a sales force of 40. Brussels-based Solvay announced the deal on June 11, agreeing to pay $12 per share for the nearly 9 mil. outstanding Unimed shares.

UsernamePublicRestriction

Register

PS034531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel